Science: Knick out this epigenetic gene to make CAR-T more effective

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

Science: Knick out this epigenetic gene to make CAR-T more effective

• Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
• Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
• FDA has mandated a top-level black box warning for all marketed CAR-T therapies
• Can people with high blood pressure eat peanuts?
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

Science: Knick out this epigenetic gene to make CAR-T more effective.

CAR-T , namely chimeric antigen receptor T cell immunotherapy.

To put it simply, CAR-T is to transform the patient’s immune T cells in vitro through biotechnology to make them recognize the antigens on the surface of tumor cells, and then inject these cells back into the patient’s body to achieve the therapeutic effect of identifying and killing cancer cells.

In 2017, the FDA approved CAR-T therapy for the first time for the treatment of blood cancers such as leukemia and lymphoma.

The successful application of CAR-T therapy has rekindled hope for many desperate people who are waiting for bone marrow matching.

It also marks the arrival of the era of cell therapy.

Today, CAR-T has become one of the most important new developments in cancer immunotherapy, and many breakthroughs have been made in hematological tumors, but CAR-T therapy is usually limited by T cell depletion.

However, those CAR-T cells that lack the DNA methyltransferase 3α (DNMT3A) gene generally have the ability to continuously attack cancer cells.

Recently, researchers from the US St. Jude Children’s Research Hospital  published a report entitled: the Deleting DNMT3A in CAR T cells enhances antitumor Activity Prevents exhaustion and research papers in Science sub-Journal Science Translational Medicine journal.

The study showed that knocking out the DNA methyltransferase 3α (DNMT3A) gene of CAR-T cells can prevent T cell exhaustion and enhance anti-tumor activity . These results indicate that DNMT3A can be used as a general target to improve the effect of CAR-T therapy, providing a new roadmap for the development of more effective CAR-T cell therapy.

CAR-T cell therapy is completely changing the treatment of human cancer. In addition to achieving remarkable results in some blood cancers, more and more studies have begun to use CAR-T cell therapy to pierce solid tumors and chronic viruses.

Although clinical trials have proven the therapeutic potential of CAR-T cell therapy, CAR-T cell therapy is facing an important problem- CAR-T cell exhaustion , CAR-T cells in the tumor microenvironment will be affected by continuous antigen stimulation. Becomes unresponsive, inhibits more and more receptors, and loses effector functions. However, the specific mechanism behind this is still unclear.

Previously, the research team has been working on bone marrow transplantation and cell therapy.

They confirmed that epigenetic regulation is directly involved in T cell failure , and T cell failure has a great impact on the clinical response of cell therapy.

The research team also studied DNA methyltransferase 3α (DNMT3A) in a mouse model and in the context of chronic viral infection .

These studies have shown that epigenetic regulators regulate long-term T cell memory.

In this study, the research team found that CAR-T cell depletion is caused by epigenetic suppression of the pluripotent developmental potential of T cells.

After knocking out the DNA methyltransferase 3α (DNMT3A) gene in CAR-T cells, these CAR-T cells can generally retain their proliferation and anti-tumor response capabilities during prolonged exposure to tumors.

The research team further revealed that the enhancement of CAR-T cell function caused by knocking out the DNMT3A gene is combined with the upregulation of interleukin 10 (IL-10) , and the gene map for epigenetic silencing was defined through genome-wide methylation analysis.

This map analyzes CAR-T cell depletion at the molecular level, including many transcriptional regulators that limit the “stemness” of immune cells, including CD28, CCR7, TCF7 and LEF1.

Finally, the research team also proved that this epigenetic regulation is closely related to the clinical results of previous CAR-T cell therapies.

These data document the key role of epigenetic mechanisms in limiting the fate potential of human T cells, and provide a roadmap for using this information to improve the efficacy of CAR-T cell therapy.

Regarding these findings, the paper’s co-corresponding author Giedre Krenciute said that CAR-T therapy is tumor-specific and may be more effective and safer than conventional therapies such as chemotherapy or radiotherapy.

This study shows that no matter which tumor type or antigen is targeted, knocking out the DNMT3A gene of CAR-T cells will indeed be more effective.

This highlights the core role of DNMT3A in controlling the function of human CAR-T cells, and it is hoped that this research will enter clinical transformation as soon as possible.

Professor Stephen Gottschalk , the co-corresponding author of this study and the head of the Department of Bone Marrow Transplantation and Cell Therapy at St. Jude Children’s Research Hospital , said that this study demonstrates the great advantages of bringing together researchers with complementary expertise.

This study combines With the advantages of synthetic biology and gene editing, it is expected to develop more effective immunotherapy for cancer patients.

Paper link:
https://www.science.org/doi/10.1126/scitranslmed.abh0272

Science: Knick out this epigenetic gene to make CAR-T more effective.

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.